1. Scrip
  2. >>Focus On Asia
  3. >>Japan

PRISM BioLab Completes Successful Tokyo IPO On Back Of Multiple Partnerships

Raises $11.5m

 
• By Lisa Takagi

The Japanese drug discovery bioventure builds on multiple alliances and an in-house platform to get away a successful IPO in Tokyo, which it will use to fund further pipeline and technology development.

PRISM BioLab successfully entered Tokyo Stock Exchange Market's Growth section on 2 July 2024.
PRISM BioLab successfully entered Tokyo Stock Exchange Market's Growth section on 2 July 2024. • Source: Shutterstock

PRISM BioLab got away a successful initial public offering on 2 July on the Tokyo Stock Exchange's Growth Market for venture firms, raising close to $12m for the drug discovery-focused Japanese bioventure.

The float followed the close of a JPY1.5bn series C fundraising in January that was backed by existing partner

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

Viatris Looks To Expand Japan Presence With Aculys Acquisition

 
• By Lisa Takagi

Global generics-focused giant acquires Japanese venture with late-stage, two-asset CNS pipeline as it looks to build presence in Japan.

Zolbetuximab Loses GLEAM In Pancreatic Cancer

 
• By Lisa Takagi

Astellas's first-in-class CLDN18.2-targeting antibody has missed its primary endpoint in a Phase II trial for pancreatic cancer and is facing increasingly fierce same-class competition in this and other indications.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.

More from Focus On Asia

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population

 
• By Dexter Jie Yan

Besting BeOne Medicines’ Tevimbra plus chemotherapy, interim results from the head-to-head HARMONi-6 study of Akeso's ivonescimab plus chemotherapy show the combo might have the longest PFS versus its single-target immuno-oncology competitors.

Asia Deal Watch: Chugai Teams With Rani On Oral Version Of Rare Disease Antibody Drug

 
• By Joseph Haas, Jung Won Shin, Lisa Takagi, Xu Hu, and Vibha Ravi

Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.

Hansoh/Roche ADC Deal Caps Chinese One-Day Licensing Spree

 
• By Dexter Jie Yan

Multiple Chinese biopharma firms reach new deals with major Western and other partners in a spree of licensing deals over a one-day period, with ADCs, in vivo CAR and bifunctional fusion protein therapies among the target assets.